NeuroMab™ Anti-Siglec 7 Antibody, Clone NR195P
Functional antibody against Human Siglec-7
- Host Species:
- Mouse
- Species Reactivity:
- Human
- Applications:
- FC; Block; Inhib; In Vitro; In Vivo; Antagonist
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Formulation
Preservatives
Concentration
Purification
Purity
Endotoxin Level
Low Endotoxin < 1 EU/mg
Target
Official Name
Full Name
Alternative Names
Gene ID
Uniprot ID
Figure 1 depicts the levels of Siglec-7 surface expression and TREM2 surface expression on human dendritic cells following treatment with anti-Siglec-7 antibody 10B5 or an isotype control antibody compared to no antibody control.
Figure 10 depicts results showing that anti-Siglec-7 antibodies 4E3 and 10B5 selectively kill a subset of myeloid-derived suppressor cells (MDSC). Top row: live/dead gate by cell morphology: dead cell gate increased for S7-4E3 and S7-10B5. Middle row: live/dead cells gated using dye: dye high positive cells are dead, dye low cells are alive. Histogram: Displays live/dead cell dyes in a histogram format.
Figure 2 depicts the levels of CD11c surface expression, Siglec-7 surface expression and TREM2 surface expression on human dendritic cells after treatment with anti-Siglec-7 antibody 10B5.
Figure 3 depicts Siglec-7 and CD33 expression in peripheral blood samples from humanized NOG mice 14 days after treatment with anti-Siglec-7 antibodies of the present disclosure.
Figure 4 shows the in vivo reduction of Siglec-7 cell surface levels following antibody treatment in vivo.
Figure 5 depicts a 12-point titration curve showing the half maximal effective concentration (EC50) of Siglec-7 antibodies 4E3 and 10B5 for reducing cell surface expression of Siglec-7
Figure 6 depicts a 12-point titration curve showing the half maximal effective concentration (EC50) of Siglec-7 antibodies 4E3 and 10B5 for reducing cell surface expression of CD11c.
Figure 7 depicts tumor volume following antibody treatment in individual mice transplanted with human immune stem cells. Mice were treated with Keytruda® (pembrolizumab) anti-PD-1 antibody alone or in combination with anti-Siglec-7 antibody 10B5.
Figure 8 depicts mean tumor volume after 28 days of treatment with Keytruda® (pembrolizumab) anti-PD-1 antibody alone or in combination with anti-Siglec-7 antibody 10B5 in mice transplanted with human immune stem cells from human donor 984480112. Mean values for each treatment group are shown. Error bars represent SEM
Figure 9 depicts cells treated with an isotype control antibody (mIgG1 ) compared to anti-Siglec-7 antibody 10B5.
Publications (0)
